These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30137052)

  • 1. Differentiating Among the SGLT-2 Inhibitors: Considering Cardiovascular and Other Safety Outcomes.
    Miller EM; Wysham CH
    J Fam Pract; 2018 Aug; 67(8 suppl):S37-S42. PubMed ID: 30137052
    [No Abstract]   [Full Text] [Related]  

  • 2. SGLT-2 Inhibitors: Fighting Cardiovascular Disease Mortality in Diabetes.
    Ghaffar ZA; Anwar S; Rizvi SW
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):195. PubMed ID: 30700368
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 4. Sodium-Glucose Cotransporter 2 Inhibitors and Fournier Gangrene: A Rare and Lethal Adverse Event.
    O'Malley PA
    Clin Nurse Spec; 2019; 33(2):63-65. PubMed ID: 30730449
    [No Abstract]   [Full Text] [Related]  

  • 5. Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.
    Bethel MA; McMurray JJV
    Circulation; 2018 Mar; 137(12):1218-1220. PubMed ID: 29555706
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A meta-analysis of cardiovascular outcome trials.
    Singh AK; Singh R
    Diabetes Res Clin Pract; 2021 Feb; 172():108648. PubMed ID: 33421444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
    Lamos EM; Hedrington M; Davis SN
    Expert Opin Drug Saf; 2019 Aug; 18(8):691-701. PubMed ID: 31150300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Toft E; Rydén M
    Lakartidningen; 2018 Feb; 115():. PubMed ID: 29461566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the safety of SGLT2 inhibitors.
    Scheen AJ
    Expert Opin Drug Saf; 2019 Apr; 18(4):295-311. PubMed ID: 30933547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison chart: SGLT2 inhibitors.
    Med Lett Drugs Ther; 2020 Nov; 62(1611):e2-e4. PubMed ID: 33429417
    [No Abstract]   [Full Text] [Related]  

  • 11. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel antidiabetic drugs and cardiovascular complications].
    Pareek M; Mortensen MB; Løfgren B; Nielsen ML; Olsen MH; Andersen NH
    Ugeskr Laeger; 2018 Feb; 180(6):. PubMed ID: 29429477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry.
    Wittbrodt E; Chamberlain D; Arnold SV; Tang F; Kosiborod M
    Diabetes Obes Metab; 2019 Aug; 21(8):1985-1989. PubMed ID: 30968543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms.
    Bajaj HS; Zinman B
    Physiology (Bethesda); 2018 May; 33(3):197-210. PubMed ID: 29638185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two alcoholic liver cirrhosis patients developed diabetic ketoacidosis after SGLT2 inhibitors-prescription.
    Chao HY; Kornelius E
    J Formos Med Assoc; 2020 Dec; 119(12):1886-1887. PubMed ID: 32690358
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
    Verma S; Mazer CD; Al-Omran M; Inzucchi SE; Fitchett D; Hehnke U; George JT; Zinman B
    Circulation; 2018 Jan; 137(4):405-407. PubMed ID: 29133602
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on the efficacy and safety of sodium-glucose cotransporter 2 inhibitors in Asians and non-Asians.
    Fujita Y; Inagaki N
    J Diabetes Investig; 2019 Nov; 10(6):1408-1410. PubMed ID: 31541588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Update: new forms of therapy for type-2-diabetes].
    Fischli S
    Ther Umsch; 2020 Sep; 77(7):319-327. PubMed ID: 32996424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
    Fattah H; Vallon V
    Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.